{
    "clinical_study": {
        "@rank": "156209", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Fully Myeloablative regimen", 
                "arm_group_type": "Other", 
                "description": "For use in patients with diseases including Wiskott-Aldrich syndrome, MHC Class II deficiency, hypomorphic SCID, etc. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, cyclophosphamide 50 mg/kg IV plus MESNA on days -9 through -6, busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2 and stem cell infusion on day 0."
            }, 
            {
                "arm_group_label": "Arm B: Reduced Toxicity Ablative Regimen", 
                "arm_group_type": "Other", 
                "description": "For use in patients with diseases including SCID, CGD, CHS and other CID.  Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6, fludarabine phosphate 40 mg/m^2 IV on days -5 through -2 and stem cell infusion on day 0."
            }, 
            {
                "arm_group_label": "Arm C: Reduced Intensity Conditioning", 
                "arm_group_type": "Other", 
                "description": "For use in patients with diseases including HLH. Receives Alemtuzumab 0.2 mg/kg intravenously (IV) on days -10 through -6, fludarabine phosphate 30 mg/m^2 IV on days -6 through -3, melphalan 140 mg/m^2 IV on day -2 and stem cell infusion on day 0."
            }, 
            {
                "arm_group_label": "Arm D: No Preparative Regimen", 
                "arm_group_type": "Other", 
                "description": "For use in patients with complete SCID phenotype with no evidence of maternal engraftment or residual immune function who will be receiving their stem cell transplantation from a genotypically matched donor."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a standard of care treatment guideline for allogeneic hematopoetic stem cell\n      transplant (HSCT) in patients with primary immune deficiencies."
        }, 
        "brief_title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "SCID", 
            "Omenn's Syndrome", 
            "Reticular Dysgenesis", 
            "Wiskott-Aldrich Syndrome", 
            "Bare Lymphocyte Syndrome", 
            "Common Variable Immunodeficiency", 
            "Chronic Granulomatous Disease", 
            "CD40 Ligand Deficiency", 
            "Hyper IgM Syndrome", 
            "X-linked Lymphoproliferative Disease", 
            "Hemophagocytic Lymphohistiocytosis", 
            "Griscelli Syndrome", 
            "Chediak-Higashi Syndrome", 
            "Langerhan's Cell Histiocytosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Chediak-Higashi Syndrome", 
                "Common Variable Immunodeficiency", 
                "Granulomatous Disease, Chronic", 
                "Histiocytosis", 
                "Histiocytosis, Langerhans-Cell", 
                "Immunologic Deficiency Syndromes", 
                "Lymphohistiocytosis, Hemophagocytic", 
                "Lymphoproliferative Disorders", 
                "Wiskott-Aldrich Syndrome", 
                "Severe Combined Immunodeficiency", 
                "Leukopenia", 
                "Hyper-IgM Immunodeficiency Syndrome", 
                "Hyper-IgM Immunodeficiency Syndrome, Type 1", 
                "Granuloma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Based on diagnosis and clinical history, a determination of the most appropriate regimen\n      will be made based on the following prep plans:\n\n      Arm A: Fully Myeloablative Preparative Regimen, Arm B: Reduced Toxicity Ablative Preparative\n      Regimen, Arm C: Reduced Intensity Conditioning, Arm D: No Preparative Regimen"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of immunodeficiency or histiocytic disorder including the following:\n\n               -  Severe combined immunodeficiency (SCID - all variants)\n\n               -  Second bone marrow transplant (BMT) for SCID (after graft rejection)\n\n               -  Omenn's Syndrome\n\n               -  Reticular dysgenesis\n\n               -  Wiskott-Aldrich syndrome\n\n               -  Major histocompatibility complex (MHC) Class II deficiency (bare lymphocyte\n                  syndrome)\n\n               -  Hyper IgM Syndrome (CD40 Ligand Deficiency)\n\n               -  Common variable immunodeficiency (CVID) with severe phenotype\n\n               -  Chronic Granulomatous Disease (CGD)\n\n               -  Other severe Combined Immune Deficiencies (CID)\n\n               -  Hemophagocytic Lymphohistiocytosis (HLH)\n\n               -  X-linked Lymphoproliferative Disease (XLP)\n\n               -  Chediak-Higashi Syndrome (CHS)\n\n               -  Griscelli Syndrome\n\n               -  Langerhans Cell Histiocytosis (LCH)\n\n          -  Acceptable stem cell sources include:\n\n               -  HLA identical or 1 antigen matched sibling donor eligible to donate bone marrow\n\n               -  HLA identical or up to a 1 antigen mismatched unrelated BM donor\n\n               -  Sibling donor cord blood with acceptable HLA match and cell dose as per current\n                  institutional standards\n\n               -  Single unrelated umbilical cord blood unit with 0-2 antigen mismatch and minimum\n                  cell dose of  >5 x 10^7 nucleated cells/kg as per current institutional\n                  guidelines\n\n               -  Double unrelated umbilical cord blood units that are:\n\n                    -  up to 2 antigen mismatched to the patient\n\n                    -  up to 2 antigen mismatched to each other\n\n                    -  minimum cell dose of at least one single unit must be \u2265 3.5 x 10^7\n                       nucleated cells/kg\n\n                    -  combined dose of both units must provide a total cell dose of \u2265 5 x 10^7\n                       nucleated cells/kg\n\n          -  Age:  0 to 50 years\n\n          -  Adequate organ function and performance status.\n\n        Exclusion Criteria\n\n          -  pregnant or breastfeeding\n\n          -  active, uncontrolled infection and/or HIV positive\n\n          -  acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on\n             biopsy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652092", 
            "org_study_id": "2012OC055", 
            "secondary_id": "MT2012-10C"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A: Fully Myeloablative regimen", 
                    "Arm B: Reduced Toxicity Ablative Regimen"
                ], 
                "description": "0.3 mg/kg intravenously (IV) on days -12 through -10", 
                "intervention_name": "Alemtuzumab 0.3 mg", 
                "intervention_type": "Drug", 
                "other_name": "Campath-1H"
            }, 
            {
                "arm_group_label": "Arm A: Fully Myeloablative regimen", 
                "description": "cyclophosphamide 50 mg/kg IV on days -9 through -6", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cytoxan"
            }, 
            {
                "arm_group_label": "Arm A: Fully Myeloablative regimen", 
                "description": "busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug", 
                "other_name": "Myerlan"
            }, 
            {
                "arm_group_label": [
                    "Arm A: Fully Myeloablative regimen", 
                    "Arm B: Reduced Toxicity Ablative Regimen", 
                    "Arm C: Reduced Intensity Conditioning", 
                    "Arm D: No Preparative Regimen"
                ], 
                "description": "Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program.  A minimum of 3 x 10^8 nucleated cells/kg recipient weight will be collected with a goal of \u2265 5 x 10^8 nucleated cells/kg recipient weight.\nUmbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm.  One or two units may be used to obtain the minimum cell dose.  One of the UCB units selected for transplantation must contain \u2265 3.5 x 10^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be > 5.0 x 10^7 nucleated cells/kg.", 
                "intervention_name": "Stem Cell Transplantation", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Arm B: Reduced Toxicity Ablative Regimen", 
                "description": "40 mg/m^2 IV on days -5 through -2", 
                "intervention_name": "Fludarabine phosphate 40 mg", 
                "intervention_type": "Drug", 
                "other_name": "Fludara"
            }, 
            {
                "arm_group_label": "Arm C: Reduced Intensity Conditioning", 
                "description": "140 mg/m^2 IV on day -2", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug", 
                "other_name": "Alkeran"
            }, 
            {
                "arm_group_label": "Arm C: Reduced Intensity Conditioning", 
                "description": "0.2 mg/kg intravenously (IV) on days -10 through -6", 
                "intervention_name": "Alemtuzumab 0.2 mg", 
                "intervention_type": "Drug", 
                "other_name": "Campath 1-H"
            }, 
            {
                "arm_group_label": "Arm B: Reduced Toxicity Ablative Regimen", 
                "description": "busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug", 
                "other_name": "Myerlan"
            }, 
            {
                "arm_group_label": "Arm C: Reduced Intensity Conditioning", 
                "description": "fludarabine 30 mg/m^2 IV on days -6 through -3", 
                "intervention_name": "Fludarabine  phosphate 30 mg", 
                "intervention_type": "Drug", 
                "other_name": "Fludara"
            }, 
            {
                "arm_group_label": "Arm A: Fully Myeloablative regimen", 
                "description": "administered as per the standard institutional protocol.", 
                "intervention_name": "MESNA", 
                "intervention_type": "Drug", 
                "other_name": [
                    "mercaptoethane sulfonate Na (Na being the symbol for sodium)", 
                    "Mesnex"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mesna", 
                "Busulfan", 
                "Cyclophosphamide", 
                "Melphalan", 
                "Fludarabine monophosphate", 
                "Campath 1G", 
                "Fludarabine", 
                "Alemtuzumab", 
                "Vidarabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "immunodeficiency disorder", 
            "histiocytic disorder"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "email": "smith719@umn.edu", 
                "last_name": "Angela R. Smith, M.D.", 
                "phone": "612-626-2778"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "Masonic Cancer Center, University of Minnesota"
            }, 
            "investigator": {
                "last_name": "Angela R. Smith, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies", 
        "overall_contact": {
            "email": "smith719@umn.edu", 
            "last_name": "Angela R. Smith, M.D.", 
            "phone": "612-626-2778"
        }, 
        "overall_official": {
            "affiliation": "Masonic Cancer Center, University of Minnesota", 
            "last_name": "Angela R. Smith, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.", 
            "measure": "Neutrophil Engraftment", 
            "safety_issue": "No", 
            "time_frame": "Day 42"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652092"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.", 
                "measure": "Incidence of Graft Failure", 
                "safety_issue": "No", 
                "time_frame": "Day 100"
            }, 
            {
                "description": "a state in bone marrow transplantation in which bone marrow and host cells exist compatibly without signs of graft-versus-host rejection disease.", 
                "measure": "Incidence of Chimerism", 
                "safety_issue": "No", 
                "time_frame": "Day 100, 6 Months, 1 Year"
            }, 
            {
                "description": "Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.", 
                "measure": "Incidence of Acute Graft-Versus-Host Disease", 
                "safety_issue": "Yes", 
                "time_frame": "Day 100"
            }, 
            {
                "description": "Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.", 
                "measure": "Incidence of Chronic Graft-Versus-Host Disease", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months and 1 Year"
            }, 
            {
                "description": "In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation.", 
                "measure": "Incidence of Transplant-Related Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months"
            }, 
            {
                "description": "the length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.", 
                "measure": "Disease-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "description": "Overall survival will be defined as time from enrollment to date of death or censored at the date of last documented contact for patients still alive.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }
        ], 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}